NASDAQ: CGEMCullinan Oncology Inc Stock
$10.53+0.37 (+3.64%)
Updated Jun 2, 2023
CGEM Price
$10.53
Fair Value Price
$3,358.56
Market Cap
$414.47M
52 Week Low
$7.78
52 Week High
$15.89
P/E
7.92x
P/B
0.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$65.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$156M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGEM Overview
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGEM ($10.53) is undervalued by 99.69% relative to our estimate of its Fair Value price of $3,358.56 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CGEM ($10.53) is significantly undervalued by 99.69% relative to our estimate of its Fair Value price of $3,358.56 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CGEM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more CGEM due diligence checks available for Premium users.
Be the first to know about important CGEM news, forecast changes, insider trades & much more!
CGEM News
Valuation
CGEM fair value
Fair Value of CGEM stock based on Discounted Cash Flow (DCF)
Price
$10.53
Fair Value
$3,358.56
Undervalued by
99.69%
CGEM ($10.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGEM ($10.53) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CGEM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7.92x
Industry
11.51x
Market
52.69x
CGEM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CGEM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CGEM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.85x
Industry
5.2x
CGEM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGEM's financial health
Profit margin
Revenue
$0.0
Net Income
-$58.0M
Profit Margin
0%
CGEM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$515.0M
Liabilities
$29.3M
Debt to equity
0.06
CGEM's short-term assets ($399.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGEM's short-term assets ($399.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$51.0M
Investing
$15.2M
Financing
$1.8M
CGEM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGEM vs Biotech Stocks
Cullinan Oncology Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.